Scientists Find a Receptor That Drives Morphine Tolerance

A receptor that helps wire the developing nervous system also appears to help morphine wear off, according to a study published September 30 in the journal Advanced Science. When researchers removed it from pain-sensing neurons in mice, morphine produced stronger and longer-lasting pain relief without raising the animals' baseline sensitivity to pain.

The work, from the Southern University of Science and Technology in Shenzhen, China, describes a molecular pathway the authors say could eventually be targeted to slow opioid tolerance — the escalating dose spiral that pushes patients toward dependence and overdose as chronic pain treatment stretches on.

The receptor is EphB1, part of the largest family of receptor tyrosine kinases in the body. It was previously best known for guiding neural circuits during development. The study's first observation was that a spinal injection of morphine rapidly switched EphB1 on in the dorsal root ganglia, clusters of sensory neurons that sit outside the spinal cord, and in the spinal cord itself. Morphine also raised levels of ephrinB2, the ligand that activates the receptor. That effect depended on the mu-opioid receptor, the same molecule through which morphine produces analgesia.

In other words, the drug appears to trigger part of its own weakening.

What blocking the receptor changed

To test whether the pathway interferes with pain relief, the team injected mice's spinal canals with ephrinB2-Fc, a laboratory reagent that activates EphB1. Even at a low dose that did not change pain sensitivity on its own, it blunted morphine's effect in the tail-flick and hot-plate tests, both standard measures of pain response in rodents.

The interference was selective. The activator dulled the analgesia produced by DAMGO, a drug that targets mu-opioid receptors specifically, but left untouched two compounds acting on the delta and kappa opioid receptor subtypes. That pattern pointed to a relationship with the mu receptor in particular rather than with opioid signaling in general.

Removing EphB1 produced the mirror image. Mice engineered to lack the receptor in neurons expressing Vglut2, a marker of excitatory neurons found in the dorsal root ganglia and the spinal dorsal horn, got markedly stronger pain relief from morphine than normal animals, while their baseline pain thresholds stayed the same. The enhancement held in two disease models as well: mice with a partial sciatic nerve ligation, a model of neuropathic pain, and mice with lung cancer cells implanted in the tibia, a model of bone cancer pain.

Experiments that deleted the receptor only in sensory neurons, or only in the spinal cord, produced the same result, and imaging showed EphB1 and the mu-opioid receptor sitting together in the same cells — co-expressed in roughly 30 percent of the Vglut2-positive neurons in the dorsal horn.

The mechanism: pulling receptors off the surface

Electrophysiology suggested the reason. Opioids quiet pain pathways in part by shutting down voltage-gated calcium channels in sensory neurons, reducing the release of pain-signaling neurotransmitters. In neurons without EphB1, morphine suppressed those calcium currents more powerfully than in control cells, and produced larger outward potassium currents, a hallmark of opioid receptor activation.

The underlying mechanism turned out to be receptor trafficking. When the mu-opioid receptor is phosphorylated at a specific amino acid, serine 375, an enzyme called GRK2 tags it and the adaptor protein beta-arrestin drags it off the cell surface and into the cell's interior, where morphine can no longer reach it. Activating EphB1 pushed the receptors off the membrane and amplified that internalization; deleting EphB1 reduced the phosphorylation. The researchers found that EphB1 clusters with the mu-opioid receptor and GRK2 into a single complex, making the receptor a regulator of the very enzyme that silences it.

The findings, the authors write, "support the idea that activation of EphB1 receptors may facilitate the development of opioid tolerance through regulating" the mu-opioid receptor.

Why tolerance is a clinical problem

Tolerance is one of the central reasons long-term opioid therapy becomes hazardous. As the same dose stops working, patients need more to get the same relief, and higher doses carry more respiratory depression, more sedation and a larger supply to divert. Federal agencies have spent years trying to reduce blanket dose escalation while preserving access for people in genuine pain, and clinicians still lack a way to keep a stable dose working.

A target that could preserve morphine's effect without adding opioid load would matter for both sides of that balance — for patients with cancer pain or severe chronic pain on long-term therapy, and for the much larger group whose exposure to prescription opioids precedes a prescription drug use disorder.

It would not, on its own, address opioid use disorder, which is treated with buprenorphine, methadone and naltrexone rather than with morphine-sparing strategies.

The limits of the evidence

Everything reported here comes from mice and cell cultures. Species differences in pain circuitry and receptor pharmacology are substantial, and a compound that blocks EphB1 safely in humans does not yet exist. The study did not test whether the enhanced analgesia persists with repeated dosing over long periods, which is the question any tolerance-directed therapy would have to answer.

The work also required genetic deletion of the receptor or direct spinal injection of reagents, neither of which translates directly into a pill or an injection for patients. EphB1 helps guide nervous system development, so blocking it systemically raises its own safety questions.

For now the paper is best read as mechanism rather than medicine: a specific, testable explanation for why opioids erode their own effectiveness, and a new place for drug developers to look.